Mayor of London announces record £22m new innovation funding to mark the start of London Life Sciences Week
• Mayor of London, Sadiq Khan, announces £22m from London's allocation of the Local Innovation Partnerships Fund (LIPF) to fund three separate projects, supporting life sciences and quantum technology
• Projects announced as London Life Sciences Week begins, bringing more than 5,000 industry leaders, innovators, and investors to the capital from across the world
• Funding will support growth and innovations that benefit Londoners, with more than £120m in combined investment identified across the three projects, including pledged match funding
The Mayor of London, Sadiq Khan has today provided a new “shot in the arm” for London’s thriving life sciences sector, by announcing £22m of funding for three projects on the opening day of London Life Sciences Week.
London is a global powerhouse in life sciences, combining world-class research, entrepreneurial talent and global investment. The capital is home to more than 2,700 life sciences companies, three of the world's top 15 universities for health and clinical science, and 19 of the top 20 global pharmaceutical companies – forming an ecosystem of innovation that drives huge commercial growth and revenues, as well as creating around 40,000 jobs and countless more opportunities for Londoners. The capital attracted more investment in life sciences last year than Shanghai, Tokyo and Singapore combined.
Launched by the UK BioIndustry Association, MedCity and London & Partners (L&P), the capital’s growth agency, London Life Sciences Week is a premier gathering of more than 5,000 innovators, global investors and leaders from pharma and UK biotech companies, offering a dynamic week of networking and dealmaking.
The week is crucial for advancements in fields such as medicine and vaccine development, AI assisted drug discovery, gene therapy and diagnostics and reaffirms London’s status as a global life sciences powerhouse.
Sadiq has today confirmed that three projects have been selected for £22m of investment through London's Local Innovation Partnerships Fund (LIPF).
The funding is part of a wider UK Research and Innovation (UKRI) programme investing up to £500m to grow high-potential innovation clusters across the UK. The three projects will receive £22m in LIPF funding, alongside more than £98m in match funding, including pledged contributions, bringing the combined investment identified to over £120m. London’s total LIPF allocation is £30m with the remainder of the funds to be allocated in due course.
The life sciences projects will support new treatments to tackle cardiometabolic diseases, including obesity, diabetes, and heart disease. These conditions are a leading cause of death and health inequalities, disproportionately affecting Londoners on lower incomes and making it harder for people to work and live life to the full. Targeted improvements in hypertension alone could prevent in London more than 1,200 heart attacks, 1,800 strokes and almost 1,000 deaths, while saving the NHS around £46m and social care services £12m.
The £22m investment will support companies and innovation districts in some of the capital's fastest-growing sectors, bringing together London's public sector, businesses and universities. These include:
• A partnership between the BioInnovation Institute and King's College London to help turn cutting-edge cardiometabolic research into viable new businesses developing treatments and medical technologies that could help detect heart disease earlier and prevent serious health complications will receive £5m.
• £5m to support PHIX London, led by UCLPartners, working with NHS and private healthcare providers in the Harley Street Health District to help businesses test and scale new health technologies, including ways to better detect and monitor high blood pressure and irregular heart rhythms, and bring them into wider use.
• £12m to continue developing the London Quantum Cluster - A world-class quantum technology coalition led by UCL, Imperial College London and King’s College London. Based in the Knowledge Quarter innovation district around King’s Cross, Bloomsbury, and Euston, and across the WestTech London innovation ecosystem in West London, this will help high-growth companies test technologies, raise investment, and apply quantum technology in healthcare, transport, finance, energy, and defence, with potential applications ranging from developing new medicines to improving the efficiency of transport and energy networks.
Speaking at the Launch of London Life Sciences Week today, the Mayor of London, Sadiq Khan is expected to say:
“For centuries, our city has been a beacon of bold ideas and brilliant discoveries. From the discovery of penicillin to groundbreaking research on the structure of DNA, London has helped change the course of modern medicine and saved millions of lives in the process.
“London is one of the most exciting life sciences hubs in the world – thanks to our unique combination of world-leading research, clinical innovation and commercial expertise. But now we want to go even further and make London not just the European capital for life sciences, but the world capital.
“Today, I’m delighted to announce another major step forward. Through the Local Innovation Partnerships Fund, we’re providing a new shot in the arm for London’s life sciences sector, by investing £22 million into three innovative projects.
“Our commitment has also helped unlock nearly £100 million in match funding, sparking a chain reaction of investment that will create jobs, drive growth and fast-track innovation.”
Professor Sir Ian Chapman, UKRI Chief Executive, said: “The strength and depth of expertise, talented people and innovative companies in London is well known and is one of the qualities that draws people from all over the globe.
“The Local Innovation Partnership Fund’s investments will add to that mix and Life Sciences and quantum technologies will be among the areas it concentrates upon. UKRI is supporting local partnerships right across the UK to build on their distinctive strengths, translating innovation into impact that advances knowledge, improves lives and drives growth.”
Laura Citron OBE, CEO of London & Partners and Chair of the Frontier Innovation Board, said: “London is full of brilliant ideas and talented people. Helping those ideas succeed here has the potential to make life better for Londoners, but it also means creating exciting careers, especially in new industries like quantum.”
Professor Kevin Fenton, Regional Director of Public Health, NHS London and OHID London, said: “Preventing cardiovascular disease (CVD) is one of London's biggest public health priorities, and achieving our ambitions will require new ideas, stronger partnerships and faster adoption of proven innovations. These two complementary proposals connect research, venture development, clinical testing and NHS implementation, helping promising discoveries reach the people and communities who need them most. Together, they could strengthen London's Million Hearts and Minds prevention programme, reduce inequalities and position London as a global leader in cardiovascular innovation.”
Professor Geraint Rees, UCL Vice-Provost (Research, Innovation and Global Engagement), said: “Universities are at the heart of the quantum revolution, creating the discoveries and talent from which new technologies and companies emerge. This investment will connect London’s world-class university research more closely with industry and investors, helping quantum technologies move out of the laboratory, scale in London and deliver benefits across the economy."
Professor Shitij Kapur, Vice-Chancellor & President of King’s College London, said: “The Local Innovation Partnership Fund has been instrumental in enabling this initiative. By combining King’s research excellence and facilities with the BioInnovation Institute’s venture-building expertise, we can accelerate the translation of discoveries into new therapies and successful businesses, ultimately benefiting patients and society.”
Mark Kildea, CEO of the Harley Street Health District said: “London's independent healthcare sector can help promising technologies fulfil their potential. Many clinicians work across public and private healthcare, creating natural routes for expertise and innovation to spread. By validating new technologies in the Harley Street Health District, this programme will build the evidence needed for wider adoption and help patients in the NHS and beyond benefit more quickly. In helping innovative businesses succeed, we will improve care for patients, create jobs for local people, and help drive London's economic growth."
Professor Mary Ryan, Vice Provost Research and Enterprise, Imperial College London, said: “We’re proud to be playing a leading role in multiple Local Innovation Partnership Funding projects for London, boosting new industries and supporting businesses of the future. We have seen firsthand, through the WestTech London ecosystem, the power of bringing together higher education, the public sector and industry to turn research excellence into breakthroughs and businesses which create jobs, drive growth and improve people’s lives. What starts here in London – though the work of the London Quantum Cluster and the other LIPF projects – will impact the local and national innovation economy.”
London’s life sciences firms have raised $3.2bn in venture capital in 2026, 35% more than in the whole of 2025 ($2.4bn), according to Dealroom figures analysed by L&P *. London ranked first in Europe for life sciences investment in 2026 and raised more than three times as much as Paris ($933m).
At the heart of London Life Sciences Week is the Jeffries Global Healthcare Conference, which is bringing together some of the leading voices in healthcare from across the world.
The investment will build on London's strengths in research and innovation, including in Euston and the wider Knowledge Quarter, home to world-leading institutions such as UCL, the Francis Crick Institute and the Alan Turing Institute. With major investment in transport infrastructure and opportunities for new commercial space, Euston has the potential to become an even stronger centre for life sciences, quantum technology and innovation.
Notes to editors
* Locations fundings heatmap | Dealroom.co.
London’s Frontier Innovation Board chose the funding priorities. It brings together leaders from government, universities, business, and investment. The projects were selected following an open call led by the Greater London Authority and were also assessed by an independent expert panel convened by UKRI. UKRI and the Greater London Authority (GLA) will manage grants to the projects.
The investment also supports London's ambition to become a Health Innovation Zone, bringing together the NHS, researchers and businesses to help promising innovations benefit Londoners’ health more quickly. The Health Innovation Zone will provide a framework for accelerating the development and adoption of innovation across health and care, building on London's world-leading life sciences sector. This work will start with one of London’s biggest priorities – heart health.
The Local Innovation Partnerships Fund (LIPF) is a flagship UK government programme, delivered through UK Research and Innovation (UKRI) investing £500 million to strengthen regional innovation economies across the country.
The LIPF is a central pillar of the government's commitment to achieve growth in every postcode. It brings together local leaders, businesses, and research organisations to build on regional strengths to create new jobs, drive innovation-led productivity, and attract further public and private investment into communities across the UK.
London’s total LIPF allocation is £30m. A small amount of the overall allocation is currently unallocated.
Frontier Innovation in Cardiometabolic Disease: Venture Builder is co-led by BioInnovation Institute (BII) UK Ltd and King’s College London.
Frontier Innovation for CMD: Validate and Scale (PHIX) is led by UCLPartners. Its delivery partners are Harley Street Health District (HSHD), AlbionVC, and the London Health Innovation Networks (Imperial College Health Partners, Health Innovation Network South London, and UCLPartners).
Strengthening London Quantum Ecosystem is led by the London Quantum Cluster, which is founded by University College London (UCL), Imperial College London and King’s College London.
The consortiums partners include:
• Industry partners: IBM, Nvidia, Quantinuum, Amazon, Rohde & Schwarz, Nu Quantum, Lendlease, Plug & Play, Quantum Motion, Phasecraft, Skydiamond, Canary Wharf Group, and Kadans Science Partners.
• Knowledge institutions: National Physical Laboratory and Institute of Physics.
• Quantum-focused investors: Quantum Exponential, Serendipity Capital, Albion Capital, and Edenbase.
• Innovation districts: Knowledge Quarter and WestTech London, including White City Innovation District.
• The London Boroughs of Hammersmith & Fulham, Camden & Islington.
• The GLA and London & Partners.
Notable companies and attendees at London Life Sciences Week:
• The Rt Hon Jonathan Reynolds MP, Secretary of State for Business, Innovation, Science and Trade and President of the Board of Trade
• Baroness Nicola Blackwood (Chair, Health Data Research Service) – Health data and life sciences leader
• Professor Dame Molly Stevens (John Black Professor of Bionanoscience, University of Oxford) – Pioneering bionanoscience researcher
• Steve Bates (Executive Chair, Office for Life Sciences) – UK life sciences policy leader
• Gil Bar-Nahum (Managing Director & EMEA Head of Biotechnology, Jefferies) – Leading biotech investment banker
Companies:
• Relation – TechBio drug discovery company
• Recursion – AI-enabled drug discovery company
• Luma Health – Healthcare patient engagement platform
• GSK – Global biopharma company